United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 2,176 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $127.11, for a total transaction of $276,591.36. Following the sale, the chief executive officer now directly owns 3,245 shares of the company’s stock, valued at $412,471.95. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of United Therapeutics Corporation (UTHR) traded up 1.73% during trading on Friday, hitting $129.22. 65,353 shares of the stock traded hands. The firm has a 50 day moving average price of $130.70 and a 200-day moving average price of $135.52. The company has a market cap of $5.61 billion, a PE ratio of 14.99 and a beta of 1.51. United Therapeutics Corporation has a one year low of $110.90 and a one year high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.61 by $4.86. The company had revenue of $444.60 million during the quarter, compared to analyst estimates of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.42 earnings per share. Analysts anticipate that United Therapeutics Corporation will post $10.70 earnings per share for the current fiscal year.

United Therapeutics Corporation announced that its board has initiated a stock repurchase program on Thursday, April 27th that authorizes the company to repurchase $250.00 million in outstanding shares. This repurchase authorization authorizes the biotechnology company to purchase up to 4.6% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

ILLEGAL ACTIVITY WARNING: “Martine A. Rothblatt Sells 2,176 Shares of United Therapeutics Corporation (NASDAQ:UTHR) Stock” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/11/martine-a-rothblatt-sells-2176-shares-of-united-therapeutics-corporation-nasdaquthr-stock.html.

A number of equities analysts have weighed in on the stock. UBS AG reissued a “sell” rating and issued a $106.00 price objective on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. ValuEngine raised shares of United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 13th. BidaskClub cut shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Jefferies Group LLC reissued a “sell” rating and issued a $105.00 price objective on shares of United Therapeutics Corporation in a research report on Friday, July 14th. Finally, Zacks Investment Research cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Six investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. United Therapeutics Corporation presently has a consensus rating of “Hold” and a consensus price target of $134.50.

Hedge funds have recently bought and sold shares of the company. First Midwest Bank Trust Division bought a new stake in United Therapeutics Corporation during the first quarter valued at about $1,057,000. Dock Street Asset Management Inc. raised its stake in United Therapeutics Corporation by 21.5% in the first quarter. Dock Street Asset Management Inc. now owns 35,455 shares of the biotechnology company’s stock valued at $4,800,000 after buying an additional 6,280 shares in the last quarter. Meritage Portfolio Management raised its stake in United Therapeutics Corporation by 1.3% in the first quarter. Meritage Portfolio Management now owns 37,801 shares of the biotechnology company’s stock valued at $5,117,000 after buying an additional 502 shares in the last quarter. Profund Advisors LLC raised its stake in United Therapeutics Corporation by 0.8% in the first quarter. Profund Advisors LLC now owns 24,714 shares of the biotechnology company’s stock valued at $3,346,000 after buying an additional 187 shares in the last quarter. Finally, Korea Investment CORP raised its stake in United Therapeutics Corporation by 1.6% in the first quarter. Korea Investment CORP now owns 97,700 shares of the biotechnology company’s stock valued at $13,227,000 after buying an additional 1,500 shares in the last quarter.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.